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ABSTRACT
A potential application of the human tumor stem cell colony
assay is to guide Phase II clinical investigations by identifying
classes of tumors (or individual patients) which are sensitive in
vitro to a new antitumor compound. We have tested human
tumor stem cells from 140 tumor biopsies representing 20
different tumor types for chemosensitivity to the Phase II drug
4'-(9-acridinylamino)methanesulfon-m-anisidide. In vitro sen
sitivity was defined as a reduction in the number of tumor
colony-forming cells to 30% of the control or less after a 1-hr
exposure to one-tenth of the pharmacologically achievable
plasma concentration of 4'-(9-acridinylamino)methanesulfon-
m-anisidide. In vitro sensitivity was found in 29 cases: non-
Hodgkin's lymphoma (2 of 2); cervical carcinoma (1 of 1);
sarcoma (3 of 6); neuroblastoma (1 of 2); acute myelogenous
leukemia (6 of 16); chronic myelogenous leukemia (1 of 3);
melanoma (8 of 34); uterine carcinoma (1 of 5); lung carcinoma
(1 of 9); ovarian carcinoma (4 of 36); and breast carcinoma (1
of 11 ). Prospective in vitro-in vivo correlations in eight patients
with various tumor types showed that three of three patients
sensitive in vitro to 4'-(9-acridinylamino)methanesulfon-m-
anisidide responded in vivo, while five of five patients resistant
in vitro had no clinical response. The results provide support
for further evaluation of the utility of the human tumor stem cell
colony assay for targeting Phase II clinical trials.
INTRODUCTION
In 1977, Hamburger and Salmon (15) reported an in vitro
assay that permitted the growth of human tumors in soft agar.
This assay has subsequently been modified and successfully
utilized to obtain tumor colony formation in a wide variety of
human tumor types (23). A variety of morphological, cytoge-
netic, and biomarker studies have shown that the colonies are
composed of tumor cells. One of the major applications of this
assay has been to quantify the effects of anticancer drugs. The
combined experience in 316 in vitro-in vivo correlative trials
using standard cytotoxic drugs at the University of Arizona and
the University of Texas at San Antonio has demonstrated that
if a drug reduces tumor colony formation less than 70%, clinical
progression occurs over 95% of the time (2, 10, 18, 24, 31).
In contrast, if the drug reduces colony formation by greater
than 70%, an objective partial or complete clinical response
occurs in 64% of patients. The assay also has promise for
conducting "in vitro Phase II trials" and preclinical screening
for entirely new compounds.
Each year, approximately 15,000 synthetic compounds and
400 purified natural products undergo anticancer screening
with mouse tumor models at the Division of Cancer Treatment
of the National Cancer Institute (9). In this study, we have
focused on the Phase II drug m-AMSA,2 an amino acridine
derivative currently in clinical investigation. This compound
demonstrated a wide spectrum of activity in mouse tumors,
including L1210 and P388 murine leukemias, B16 melanoma,
C3H and CD8F, mammary tumors, and Colon Tumors 26 and
38 (34). Over the last 6 years, extensive Phase I and II clinical
trials have been ongoing.
The high frequency of successful prediction of in vivo re
sponses for both resistance and sensitivity to standard cyto
toxic drugs suggests that the human tumor stem cell colony
assay may allow for targeting of Phase II clinical trials. Accord
ingly, we have analyzed our experience with the Phase II drug
m-AMSA in the human tumor stem cell colony assay. We report
here our total in vitro experience with m-AMSA and 8 prospec
tive in vitro-in vivo correlations.
MATERIALS AND METHODS
Patient Material and Biopsy Specimens. All patients in this study
were seen, evaluated, and treated at the University of Arizona Cancer
Center or the Tucson Veterans Administration Hospital. All biopsy
specimens were obtained by surgical excision after informed, written
consent and prepared for culture as described previously (15, 25).
Briefly, tumor biopsies were placed in a small amount of culture media
in a sterile container and minced to approximately 1-mm square pieces
using scalpels and then passed through sterile sieves. The resulting
suspension was passed through needles of decreasing size and
washed once with McCoy's Medium 5A containing 10% heat-inacti
vated fetal calf serum.
Drug Assay. A stock solution of m-AMSA (0.1 mg/ml) was prepared
in sterile-buffered water and stored at -70Â°. Dilutions were made in
medium for cell incubation. Single-cell tumor suspensions were trans
ferred to tubes and adjusted to a concentration of 5 x 105 cells/ml
with the appropriate m-AMSA dilution or control. Each tumor was
tested, it possible, with a minimum of 3 concentrations of m-AMSA
including at least one dose calculated as equal to or less than one-
tenth of an achievable 1-hr concentration of a drug x time (C x f) level
in vivo (19). The final drug concentrations ranged from 0.0001 to 10
/ig/ml. After a 1-hr incubation, the cells were centrifuged at 150 x g
for 10 min, washed twice in medium, and plated in 35-mm Retri dishes
in 1 ml of 0.3% agar layer over a 1 ml 0.5% agar underlayer containing
an admixture of fetal bovine serum and growth factors (25). For assays
of acute nonlymphocytic leukemia cells, the blast cell clonogenic assay
designed by Buick et al. (4) was utilized, with methylcellulose as the
semisolid support.
Plates were cultured in an incubator at 37Â° in a humidified 7.5%
CO2 environment. Plates were examined serially with an inverted-phase
1Supported in part by National Cancer Institute Grants CA17094, CA21839
and CA23074.
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microscope for evidence of cluster or colony formation. This procedure
included an examination of the final plate for clumps of cells that might
be confused with colonies. In addition, a control plate was fixed and
preserved for future comparative purposes if needed. Colonies were
defined as aggregates of greater than 30 cells. At least 20 tumor
colonies/plate were required in the control plates to assure an ade
quate number for the assessment of drug effect. Plates were counted
when sufficient colonies were present (10 to 17 days). The average
cloning efficiency was 0.0327% (range, 0.0039 to 0.1632%) (see
Table 1).
Phase II Clinical Trial. Simultaneously, a broad phase II clinical trial
using m-AMSA was conducted at the University of Arizona Cancer
Center and the Tucson Veterans Administration Hospital. m-AMSA was
administered as a single agent at a dose of 120 mg/sq m i.v. every 28
days. Patients were eligible to receive m-AMSA if they had measurable
lesions, had failed standard therapy, and had a life expectancy of at
least 8 weeks. Response to therapy was described as follows: complete
response, the disappearance of all measurable lesions lasting at least
4 weeks; partial response, a decrease by at least 50% of all measurable
lesions lasting at least 4 weeks; mixed response, a decrease in some
measurable lesions with other lesions progressing or demonstrating a
response. If a patient failed to achieve a tumor regression after 2
courses of m-AMSA, the drug was discontinued, and the patient was
taken off study. In patients who achieved a partial response to m-
AMSA, the drug was continued until disease progression.
Statistical Methods. All assay data were stored on a Wang 2200-C
laboratory computer disc file. Cloning efficiencies were calculated from
the total number of cells plated and were not corrected for the propor
tion of nontumor cells in the sample. This correction was not made, as
normal cells do not form colonies in this system. All tumor specimens
have all grossly normal tissue removed prior to the preparation of a
single-cell suspension. Nevertheless, relative plating efficiencies are
difficult to compare, because the percentage of normal cells varies
from biopsy to biopsy. For the graphic presentation, the mean of
triplicate observations of the survival of TCFU for each patient was
plotted versus drug concentration.
Survival of TCFU at one-tenth the calculated pharmacologically
achievable C x f (1 hr) ("cutoff" concentration) was determined. The
cutoff concentration used was 0.1 /xg/ml. On the basis of experiments
with ovarian cancer and multiple myeloma, patients were classified as
sensitive if survival of TCFU was less than 30% at the cutoff concen
tration and resistant if greater than 30% (2, 10). This simple approach
to classifying in vitro response has developed from a careful analysis
of the more complex "area under the curve" (19). Due to the fact that
the critical concentration of a drug in the human tumor stem cell system
which can be used to predict "sensitivity" can vary from drug to drug,
it is essential in working with new drugs to utilize several different
concentrations of drug and to plot colony formation at several concen
trations. After adequate clinical correlation is available, the critical
concentration can then be determined accurately.
RESULTS
Effect of m-AMSA on Tumor Colony Formation. Stem cells
from 140 tumor biopsy specimens demonstrated greater than
20 colonies/plate and were tested against m-AMSA. Repre
sented among these 140 specimens were 20 different tumor
types (Table 1). Nine or more specimens were tested in breast
carcinoma, lung carcinoma, acute myelogenous leukemia,
ovarian carcinoma, and melanoma, and 4 or more specimens
were tested in sarcomas, bladder carcinoma, uterine carci
noma, and colon carcinoma. The percentage of tumor speci
mens which had a 70% or greater inhibition of colony formation
after exposure to m-AMSA at concentrations of 0.1 jug/ml or
less are presented in Table 1. The in vitro response rate was
higher (33% or more) in non-Hodgkin's lymphoma, acute my
elogenous leukemia, chronic myelogenous leukemia, neuro
blastoma, and sarcomas.
Prospective Correlation of in Vitro-in Vivo Effects of m-
AMSA. Eight Ã©valuablepatients in the clinical trial also under
went biopsy and had successful human tumor stem cell colony
formation prior to the initiation of therapy with m-AMSA. Chart
1 depicts the results and correlations as survival-concentration
curves; the tumor specimen from the patient with papillary
thyroid carcinoma had only enough cells to test one concen
tration of m-AMSA. The concentration of 1 ftg/ml was selected
prior to knowledge of the clinically achievable levels of m-
AMSA. The tumor specimen from the patient with lymphoma
Table 1
In vitro sensitivity of tumor stem cells to m-AMSA at 0.1 Â¡ig/ml
Sensitivity was defined as a 70% or greater inhibition of tumor colony formation
when compared to controls. Plating efficiency was calculated as the number of
colonies formed on controls as a percentage of the total number of nucleated
cells inoculated.
TumortypesNon-Hodgkin's
lymphomaCervical
carcinomaSarcomaNeuroblastomaAcute
myelogenousleukemiaChronic
myelogenousleukemiaMelanomaUterine
CarcinomaLung
carcinomaOvarian
carcinomaBreast
carcinomaBladder
carcinomaColon
carcinomaThyroid
carcinomaPancreatic
carcinomaProstatic
carcinomaMyelomaBrainSquamous
cell carcinomaofthe
head andneckTesticular
carcinomaNo.
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Chart 1. Survival-concentration curves for a 1-hr in vitro exposure of human
tumor stem cells to m-AMSA with in vivo correlation. CA, carcinoma; NLPD,
poorly differentiated modular lymphoma.
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demonstrated a significant decrease in colony formation inhi
bition at the 1-/Â¿g/mldrug concentration compared to the 0.1-
jug/ml drug concentration. This is a rare phenomenon which
has unclear significance.
The 5 patients who demonstrated less than 70% colony-
forming inhibition after a 1-hr exposure to 0.1 /ig/ml of m-
AMSA in vitro all failed to respond to m-AMSA in the clinical
trial. All 3 patients who showed a reduction in survival of
colony-forming cells to 30% or less after a 1-hr exposure to m-
AMSA (0.1 /ig/ml) had a mixed or partial clinical response to
the drug in vivo. Two of the 3 patients who were sensitive to m-
AMSA in vitro had partial responses to the drug. A patient with
poorly differentiated nodular lymphoma had a greater than
50% shrinkage of his enlarged lymph nodes, which lasted 3
months, and a patient with a large pelvic mass secondary to
cervical carcinoma achieved a greater than 50% reduction in
tumor volume, which lasted 2 months. The other response was
in a patient with metastatic melanoma who had a greater than
50% reduction in size of a grossly enlarged liver together with
improved liver function tests, while a neck mass enlarged
(mixed response). The tumor specimen from this patient was
obtained from an excisional biopsy of a separate lymph node
metastasis.
DISCUSSION
Correlative clinical trials have demonstrated that in vitro
chemosensitivity to standard cytotoxic compounds in the tumor
stem cell colony assay can predict clinical sensitivity or resist
ance with a high degree of accuracy (2, 10, 18, 24, 31). The
in vitro experience with the assay reported here involved 20
different tumor types and suggested that m-AMSA may have
clinical activity in leukemia. Our in vitro studies also suggest
that there may not be significant antitumor activity for m-AMSA
in lung carcinoma, breast carcinoma, and ovarian carcinoma.
The data available on other tumor types tested in vitro are on
a very small number of patients, and no firm conclusions can
be drawn. m-AMSA has been the subject of extensive Phase I
and II clinical trials since the late 1970's. Only a limited number
of Phase II clinical trials using m-AMSA have been published in
detail. m-AMSA appears to have minimal activity in colorectal
carcinoma, lung cancer, hypernephroma, hepatoma, head and
neck carcinoma, breast carcinoma, prostate cancer, and sar
coma (6-8, 11 -14,16, 20, 21, 26, 27, 29, 30, 35). The clinical
utility of m-AMSA in non-Hodgkin's lymphoma is unclear, but
the drug appears to be active in acute leukemia (3, 5, 28, 33).
The in vitro results in melanoma warrant separate comment.
The chemosensitivity results as reported here in 34 human
melanoma specimens would have predicted an in vivo sensitiv
ity in 8 patients (24%). One of these 8 patients did receive m-
AMSA and achieved a mixed response. In that instance, an
axillary node biopsy was tested in vitro. After initiation of m-
AMSA therapy, the patient had a striking reduction in massive
hepatomegaly in 3 weeks, but simultaneously progressed with
enlargement of a neck mass (mixed response). Only one de
tailed Phase II clinical trial with m-AMSA in melanoma has been
reported, and in that trial plus our own experience little activity
for the drug in this disease is suggested (1, 16). Therefore, we
believe that the 24% in vitro response rate may include more
"false positives" than are usually observed with this assay.
Possible explanations for this false-positive finding include: (a)
Sensitivity of Human Tumor Stem Cells to m-AMSA
the critical in vitro C x t for m-AMSA in melanoma may be less
than 0.1 jtig.hr/ml; (b) binding of m-AMSA to melanin granules
or some pharmacological quirk may distort the in vitro chemo
sensitivity results (22); (c) metastatic melanoma in any one
patient may represent a particular heterogeneous tumor with
several coexistent clones of malignant cells, each with differing
chemosensitivity patterns. (The frequency of response in vivo,
in fact, supports this latter possibility.) Additional in vitro stud
ies, in vivo-in vitro correlations, and additional pharmacological
studies in patients with melanoma treated with m-AMSA will be
required to select among these alternatives.
With regard to the prediction of chemosensitivity to m-AMSA,
the 8 prospective in vitro/in vivo trials reported in this study,
while small in number, showed an excellent (100%) correlation
with the human tumor stem cell colony assay results. These
correlations support the reliability of the human tumor stem cell
colony assay to predict in vivo responses to Phase II agents;
however, since only partial or mixed responses were achieved,
such responses were not of major clinical significance. It ap
pears probable that more stringent criteria for in vitro chemo
sensitivity (e.g., lower TCFU survival cutoff) may be required to
predict complete responses successfully.
The major objective of Phase II clinical trial is to determine if
a new agent has anticancer activity in humans. As currently
conducted by the Division of Cancer Treatment of the National
Cancer Institute, Phase II clinical trials have a number of
problems (32). Evaluations are performed on extensively pre-
treated patients. A limited number of tumor types are tested.
The process is expensive, it takes from 3 to 7 years to com
plete, and patients incur significant morbidity with a low prob
ability of benefit. The human tumor stem cell colony assay
provides a new methodology with which to evaluate potential
Phase II agents and may allow identification of tumor types and
specific patients who might benefit from a new drug. Our in
vitro studies of m-AMSA together with 8 in vivo correlations
support further investigations of this approach.
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